Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Økonomisk Ugebrev Life Science Investor Conference (April 2022)
22 slides from Expres2ion Biotech Holding Ab's conference presentation, April 2022
Slide 1: Proteins for Life
ExpreS2ion Biotech Holding AB Økonomisk Ugebrev / Investor Pitch April 2022 Proteins for Life Bent U. Frandsen, CEO A prospectus has been prepared in connection with the Rights Issue, which is referred to in this Presentation, and has been reviewed and approved by the Swedish Financial Supervisory A
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by ExpreS2ion Biotech Holding AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus, backed up by Contract Research Organization (CRO) business, that has generated SEK 60 million since IPO in 2016 Vaccine development
Slide 4: Management Team
Management Team >200 years of professional skills and experience from the life sciences industry Management Board of Directors • Bent U. Frandsen, Chief Executive Officer • Dr. Martin R. Jensen, Chairman & Co-founder • Keith Alexander, Chief Financial Officer • Dr. Allan Rosetzsky, Member of the Boa
Slide 5: Rights Issue
Rights Issue De-risking the pipeline development Maximum number of new shares to be issued: 5,841,273 Raising approx. 73 million SEK in gross proceeds Subscription price of SEK 12.50 per share Use of Proceeds Complete pre-clinical safety studies Three rights for every eight shares; Two rights entitl
Slide 6: ExpreS2ion's Business Model
2 ExpreS ion’s Business Model High-potential pipeline and revenue generating CRO business ExpreS2 Platform for Protein Expression +500 different proteins have been produced with the ExpreS2 platform, while posting a success rate exceeding 90% across +100 clients and partners. Novel Pipeline Developm
Slide 7: Technology Platforms
Technology Platforms ExpreS2ion’s ExpreS2 and AdaptVac’s cVLP platform Particle (VLP) technology AdaptVac’s proprietary virus-like particles (VLP) technology Cell line derived from Drosophila melanogaster securely attaches our proteins to (fruit fly) S2 cells1 the surface of a capsid (outer protein
Slide 8: ExpreS2 and AdaptVac's VLP
2 ExpreS and AdaptVac’s VLP The platforms combined enable powerful vaccines to handle a wide range of diseases ExpreS2, advantages in discovery manufacturing AdaptVac’s cVLP platform, high immunogenic potential ✓ Rapid delivery (3-6 months) of high-quality and uniform ✓ Full length proteins: Excepti
Slide 9: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Pharmacology Phase III Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II initiation: H1 2022 PREVENT-nCoV Phase I 100% Breast Canc
Slide 10: Our Programs
Our Programs Proteins for Life
Slide 11: Breast Cancer Overview
BREAST CANCER Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Monoclonal antibodies are the cornerstone of treatment Serious drawbacks exist with these therapies2 for HER2+ breast cancer (>USD 11bn sales)1 • Resistance to monoclonal a
Slide 12: ES2B-C001 Overcomes Herceptin Resistance
BREAST CANCER ES2B-C001 Overcomes Herceptin Resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence UNTREATED ES2B-C001 Trastuzumab- sensitive HER2+ human cancer cells1 Both Herceptin (trastuzumab) and ES2B-C001 inhibited growth in the trastuzumab-sensitive cell
Slide 13: ES2B-C001 Preclinical Proof-of-Concept
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept ES2B-C001 has demonstrated animal proof-of-concept Effectively inhibited tumor development Prevented tumor development with 95% efficiency Tumor growth in FVB mice (HER2-intolerant) ES2B-C001 with adjuvant (n=20) Control (n = 10) Untreated (n=26)
Slide 14: The 2nd Generation COVID-19 Vaccine
CORONAVIRUS nd The 2 Generation COVID-19 Vaccine With over 6 million deaths worldwide1, significant needs remain in the global long-term fight against the SARS-CoV-2 virus: Uncertain duration of effect with current vaccines, expected to need repeated boosters Storage and handling requirements for ma
Slide 15: ABNCoV2 COVID-19 Vaccine
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Successful completion of Phase II study, and initiation of Phase III in H1 2022 Phase II: Safe & highly efficacious against SARS-CoV-2 Phase III: Initiation of pivotal study in H1 2022 • Favorable safety profile: Vaccine was generally well-tolerated, with no rela
Slide 16: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receive from Bavarian Nordic ExpreS2ion receive from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in
Slide 17: Financials and Outlook
Financials and Outlook Proteins for Life
Slide 18: Financials – Fitting the New Strategy
Financials – Fitting the New Strategy Revenues, SEK ‘000s Operating costs, SEK ‘000s Cash balance1, SEK million 6.000 160 0 142 139 5.000 140 -3.000 4.000 120 107 108 3.000 -6.000 100 83 2.000 -9.000 80 1.000 -12.000 60 0 -15.000 40 30 -18.000 20 13 Net sales Other operating income 10 5 3 5 6 -21.00
Slide 19: Rights Issue – what do I need to do?
Rights Issue – what do I need to do? Subscription in new shares Investors with or without preferential rights can subscribe for new shares through their: 1. Own registered accounts – where you either can register interest in new shares through: a) Your bank respectively (etc. Avanza, Nordnet), where
Slide 20: Timetable
Timetable Event Timing Last day of trading in shares including right to receive 11 April 2022 subscription rights First day of trading in shares excluding right to 12 April 2022 receive Subscription rights Record date for participation in the Rights Issue 13 April 2022 Prospectus published 13 April
Slide 21: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 CORONAVIRUS (ABNCoV2) BN Phase II BN Phase II BN Phase III BN Phase III BN ready for study initiation study readout study initiation initial readout market launch (Q3’21) H1 2022 H1 2022 H2 2022 (subject to regulatory approval) BREAST CANCER (ES2B-C001)
Slide 22: Proteins for Life
Thank you! Contact: info@expreS2ionbio.com Proteins for Life
ExpreS2ion Biotech Holding — Økonomisk Ugebrev Life Science Investor Conference (April 2022) on 6ix